Copyright
©The Author(s) 2025.
World J Transplant. Sep 18, 2025; 15(3): 101997
Published online Sep 18, 2025. doi: 10.5500/wjt.v15.i3.101997
Published online Sep 18, 2025. doi: 10.5500/wjt.v15.i3.101997
Table 1 Demographics and clinical characteristics of patients waitlisted for liver transplantation for non-alcoholic steatohepatitis-associated hepatocellular carcinoma, n (%)
| Non-Hispanic White (n = 2713) | Non-Hispanic Black (n = 41) | Hispanic (n = 891) | Asian (n = 115) | Other (n = 50) | Overall P value | |
| Age, median (IQR) (years) | 64.0 (59.0, 68.0) | 62.0 (56.0, 68.0) | 63.0 (59.0, 67.0) | 65.0 (60.0, 68.0) | 63.0 (58.0, 67.0) | 0.002 |
| Male sex | 1945 (71.7) | 20 (48.8) | 465 (52.2) | 65 (56.5) | 30 (60.0) | < 0.001 |
| Body mass index, median (IQR) (kg/m2) | 32.6 (29.0, 36.6) | 32.6 (28.7, 37.7) | 31.6 (28.1, 35.2) | 27.5 (25.0, 30.5) | 34.8 (29.4, 37.7) | < 0.001 |
| Days on wait list, median (IQR) | 217 (100, 355) | 190 (59, 317) | 265 (140, 424) | 311 (195, 496) | 206.5 (102, 360) | < 0.001 |
| History of diabetes at listing | 1845 (68.1) | 20 (48.8) | 603 (68.1) | 81 (70.4) | 32 (64.0) | 0.11 |
| Encephalopathy at listing | 1339 (49.4) | 15 (36.6) | 422 (47.4) | 37 (32.2) | 26 (52.0) | 0.003 |
| Ascites at listing | 1666 (61.4) | 24 (58.5) | 511 (57.4) | 53 (46.1) | 26 (52.0) | 0.004 |
| Laboratory model for end-stage liver disease at listing, median (IQR) | 12.0 (9.0, 17.0) | 13.0 (8.0, 18.0) | 12.0 (9.0, 17.0) | 10.0 (8.0, 15.0) | 13.0 (9.0, 20.0) | 0.01 |
| Albumin at listing, median (IQR) | 3.3 (2.9, 3.7) | 3.1 (2.5, 3.8) | 3.2 (2.8, 3.6) | 3.3 (2.9, 3.8) | 3.2 (2.6, 3.6) | < 0.001 |
| Creatinine at listing, median (IQR) (mg/dL) | 0.9 (0.8, 1.2) | 1.0 (0.8, 1.2) | 0.8 (0.7, 1.1) | 0.8 (0.7, 1.1) | 1.0 (0.8, 1.4) | < 0.001 |
| Bilirubin at listing, median (IQR) (mg/dL) | 1.6 (1.0, 2.7) | 1.8 (0.7, 4.3) | 1.6 (1.0, 2.8) | 1.5 (0.8, 2.1) | 1.6 (1.1, 3.6) | 0.17 |
| Received hepatocellular carcinoma exception points | 2034 (75.0) | 28 (68.3) | 703 (78.9) | 91 (79.1) | 37 (74.0) | 0.10 |
| Functional status at listing | < 0.001 | |||||
| Unknown | 68 (2.5) | 0 (0.0) | 6 (0.7) | 0 (0.0) | 0 (0.0) | |
| 10 | 3 (0.1) | 0 (0.0) | 3 (0.3) | 0 (0.0) | 0 (0.0) | |
| 20 | 36 (1.3) | 1 (2.4) | 20 (2.2) | 3 (2.6) | 1 (2.0) | |
| 30 | 57 (2.1) | 2 (4.9) | 30 (3.4) | 0 (0.0) | 3 (6.0) | |
| 40 | 195 (7.2) | 0 (0.0) | 34 (3.8) | 4 (3.5) | 4 (8.0) | |
| 50 | 299 (11.0) | 10 (24.4) | 85 (9.5) | 8 (7.0) | 6 (12.0) | |
| 60 | 398 (14.7) | 7 (17.1) | 149 (16.7) | 17 (14.8) | 7 (14.0) | |
| 70 | 626 (23.1) | 7 (17.1) | 231 (25.9) | 26 (22.6) | 6 (12.0) | |
| 80 | 615 (22.7) | 8 (19.5) | 198 (22.2) | 26 (22.6) | 11 (22.0) | |
| 90 | 338 (12.5) | 5 (12.2) | 106 (11.9) | 23 (20.0) | 8 (16.0) | |
| 100 | 78 (2.9) | 1 (2.4) | 29 (3.3) | 8 (7.0) | 4 (8.0) | |
| Working for income at registration | 774 (28.8) | 12 (29.3) | 195 (22.1) | 38 (33.0) | 20 (40.0) | < 0.001 |
| Listing era | 0.24 | |||||
| Pre-MMAT era (1/1/2015-5/31/2019) | 1653 (60.9) | 27 (65.9) | 517 (58.0) | 75 (65.2) | 26 (52.0) | |
| Post-MMAT era (6/1/2019-12/31/2021) | 1060 (39.1) | 14 (34.1) | 374 (42.0) | 40 (34.8) | 24 (48.0) | |
| Candidate final status | 0.01 | |||||
| Died | 132 (4.9) | 2 (4.9) | 66 (7.4) | 6 (5.2) | 4 (8.0) | |
| Transplanted | 2127 (78.4) | 31 (75.6) | 638 (71.6) | 93 (80.9) | 37 (74.0) | |
| Other | 454 (16.7) | 8 (19.5) | 187 (21.0) | 16 (13.9) | 9 (18.0) |
- Citation: Victor DW, Kodali S, Noureddin M, Brombosz EW, Lopez A, Basra T, Graviss EA, Nguyen DT, Saharia A, Connor AA, Abdelrahim M, Cheah YL, Simon CJ, Hobeika MJ, Mobley CM, Ghobrial RM. Disparities in liver transplantation for metabolic dysfunction-associated steatohepatitis-associated hepatocellular carcinoma. World J Transplant 2025; 15(3): 101997
- URL: https://www.wjgnet.com/2220-3230/full/v15/i3/101997.htm
- DOI: https://dx.doi.org/10.5500/wjt.v15.i3.101997